Results 231 to 240 of about 36,146 (282)
Some of the next articles are maybe not open access.
Neovascular Age-Related Macular Degeneration
Drugs, 2008Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide, and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 years in Western societies. Choroidal neovascularization (CNV), the hallmark of 'wet', 'exudative' or 'neovascular' AMD, is responsible for approximately 90% of cases of ...
Aimee V, Chappelow, Peter K, Kaiser
openaire +2 more sources
Macular translocation for neovascular age-related macular degeneration
Cochrane Database of Systematic Reviews, 2008Macular translocation has been proposed by vitreoretinal surgeons to displace the neuroretinal tissue onto healthy retinal pigment epithelium and choroid when the macula has been invaded by subretinal neovascularisation.This review aims at assessing the effectiveness of macular translocation for preserving or improving vision in patients with ...
Eandi CM +2 more
openaire +3 more sources
Exudative non-neovascular age-related macular degeneration
Graefe's Archive for Clinical and Experimental Ophthalmology, 2020To describe the clinical and multimodal imaging (MMI) features of age-related macular degeneration (AMD) eyes presenting with intraretinal exudation and no evidence of neovascularization or structural alterations of native retinal vessels.This was a retrospective review of the MMI and electronic health records for 3 consecutive patients presenting with
Tommaso Bacci +3 more
openaire +3 more sources
Imaging in Neovascular Age-Related Macular Degeneration
Seminars in Ophthalmology, 2011Imaging plays an essential role in the diagnosis and treatment of age-related macular degeneration (AMD). This review describes the imaging modalities most commonly employed by ophthalmologists caring for patients with neovascular AMD. Imaging modalities discussed include fluorescein angiography, optical coherence tomography, indocyanine green ...
Adam J, Gess +2 more
openaire +2 more sources
Management of neovascular age-related macular degeneration
Progress in Retinal and Eye Research, 2007Neovascular age-related macular degeneration (AMD) is becoming an increasing socio-medical problem as the proportion of the aged population is continuously increasing. However, new insights in the pathogenesis of the disease offer the opportunity to develop targeted therapies that attack the disease process more successfully than ever.
Ursula M, Schmidt-Erfurth +1 more
openaire +2 more sources
Age-related Macular Degeneration and Choroidal Neovascularization
American Journal of Ophthalmology, 1993The neovascular variant of age-related macular degeneration is amenable to laser photocoagulation treatment within well-defined guidelines established by clinical trials. However, only a limited number of patients meet eligibility criteria for this form of treatment, principally because of the ill-defined, or occult nature, of the choroidal ...
K B, Freund +2 more
openaire +2 more sources
Ranibizumab for neovascular age-related macular degeneration
American Journal of Health-System Pharmacy, 2008The pharmacology, pharmacokinetics, clinical efficacy, safety, pharmacoeconomics, and place in therapy of ranibizumab are reviewed.Ranibizumab is the humanized fragment of the murine monoclonal antibody that binds all the active forms of the vascular endothelial growth factor, leading to the inhibition of the neovascular process underlying age-related ...
Luis Javier, Hernandez-Pastor +3 more
openaire +2 more sources
Ranibizumab for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine, 2006Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular ...
Philip J, Rosenfeld +6 more
openaire +2 more sources
Abicipar pegol for neovascular age-related macular degeneration
Expert Opinion on Biological Therapy, 2020The development of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized management of neovascular age-related macular degeneration (nAMD) and serves as the standard of care for treating this chronic, progressive disease.
Rehan M, Hussain +4 more
openaire +2 more sources
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ROUNDTABLE
Retina, 2005Several recent developments may provide an opportunity to improve outcome in individuals who develop neovascular age-related maculopathy (age-related macular degeneration [ARMD]). Concurrent with progress in isolating clinically relevant subtypes of neovascular ARMD, several therapies have been introduced that show promise for halting progression of ...
CHAIRMAN LAWRENCE J. SINGERMAN +6 more
openaire +1 more source